Brainomix Secures $25.4M to Accelerate U.S. AI Imaging Expansion
February 27, 2026, 3:49 pm
Brainomix, a leading AI medical imaging innovator, closed a $25.4 million Series C extension. This strategic investment boosts its U.S. market presence significantly. Funds will accelerate widespread deployment of its Brainomix 360 Stroke and e-Lung platforms. These FDA-cleared AI solutions transform acute stroke assessment and pulmonary fibrosis management. The capital also strengthens customer support across both the U.S. and Europe. Product innovation receives a significant push. Brainomix aims to deliver precision medicine. It improves clinical decision-making and patient outcomes globally. This funding round reflects strong investor confidence. It solidifies Brainomix's position in advanced healthcare technology.
Brainomix now commands $25.4 million in total Series C funding. A recent £4.8 million extension propelled this sum. The initial £14 million was secured in March 2025. This substantial capital infusion underscores investor faith. It empowers Brainomix to solidify its market footprint.
The new funding round saw key participation. Existing investors Parkwalk Advisors and Hostplus returned. They invested via the IP Group Hostplus Innovation Fund. A significant new player also joined. U.S.-based Modi Ventures invested for the first time. This new partnership signals growing interest in Brainomix's technology. It also validates its strategic U.S. expansion plans.
The United States represents a critical growth area. Brainomix will deploy the new funds strategically. It aims to deepen its U.S. market penetration. The company already possesses established U.S. operations. Its AI imaging platforms hold FDA clearance. This new capital will accelerate broader platform deployment. Hospitals across the nation will gain access.
Focused efforts will support two flagship platforms. Brainomix 360 Stroke and Brainomix 360 e-Lung are prime targets. The company will also strengthen customer support. This covers both the U.S. and European markets. Product innovation will receive a significant boost. This ensures Brainomix remains at technology's forefront.
Brainomix 360 Stroke revolutionizes acute stroke assessment. It functions as a fully automated AI imaging platform. Its impact spans the entire patient pathway. The system supports faster treatment decisions. It enables more confident transfer decisions. Speed is paramount in stroke care. Every minute saved can improve patient outcomes. This technology aids clinicians significantly. It helps them act decisively.
The platform provides vital insights. It allows for swift patient triage. This is crucial for primary stroke centers. Endovascular thrombectomy treatment rates can increase. Delays in patient transfer also reduce. Brainomix 360 Stroke makes advanced stroke care more accessible. This benefits patients regardless of local resources.
Pulmonary fibrosis presents another major healthcare challenge. Brainomix addresses this with its 360 e-Lung platform. This technology utilizes AI-driven CT biomarkers. It helps identify the disease early. It also monitors disease progression. Prediction of future trends becomes possible. This enables earlier diagnosis. Consequently, earlier treatment options emerge. Improved patient outcomes for pulmonary fibrosis sufferers become a reality.
Brainomix originated as a spinout from the University of Oxford. This lineage highlights its deep scientific roots. The company operates globally. Its reach extends to over 20 countries. Offices are strategically located. They include the UK, Ireland, and the United States. This international presence facilitates widespread adoption.
The company's core mission is clear. It aims to enable precision medicine. AI-powered imaging tools drive this goal. These tools improve clinical decision-making. They lead directly to enhanced patient outcomes. Brainomix positions itself as a leader in healthcare innovation.
The investment from Modi Ventures is noteworthy. It marks a fresh U.S. commitment. Sahir Ali, Modi Ventures Founder, expressed confidence. The platform boasts rigorous clinical validation. Real-world evidence supports Brainomix 360 Stroke's efficacy. It significantly increases treatment rates. It reduces patient transfer delays.
Modi Ventures also recognized e-Lung's potential. It called the technology truly novel. It accelerates fibrosing lung disease diagnosis. This enables earlier, more effective treatment. Such advancements promise to improve patient outcomes.
This funding ensures Brainomix's sustained growth. It strengthens its research and development capabilities. The company can now accelerate new product features. It can enhance existing platform functionalities. The focus remains on delivering cutting-edge AI solutions. These solutions address critical medical needs.
AI's role in healthcare is rapidly expanding. It offers unprecedented opportunities. Diagnostics become more precise. Treatment pathways become more personalized. Brainomix stands at the forefront of this revolution. Its platforms embody the future of medical imaging. They empower clinicians with superior tools.
The healthcare landscape constantly evolves. Hospitals face increasing pressure. They must deliver efficient, high-quality care. Brainomix provides essential support. Its AI solutions streamline workflows. They enhance diagnostic accuracy. They ultimately improve patient lives. This recent funding solidifies its trajectory. It reinforces its commitment to transformative healthcare technology. Brainomix is poised for significant impact. Its global influence continues to grow. The future of AI in medicine looks brighter.
Brainomix now commands $25.4 million in total Series C funding. A recent £4.8 million extension propelled this sum. The initial £14 million was secured in March 2025. This substantial capital infusion underscores investor faith. It empowers Brainomix to solidify its market footprint.
The new funding round saw key participation. Existing investors Parkwalk Advisors and Hostplus returned. They invested via the IP Group Hostplus Innovation Fund. A significant new player also joined. U.S.-based Modi Ventures invested for the first time. This new partnership signals growing interest in Brainomix's technology. It also validates its strategic U.S. expansion plans.
The United States represents a critical growth area. Brainomix will deploy the new funds strategically. It aims to deepen its U.S. market penetration. The company already possesses established U.S. operations. Its AI imaging platforms hold FDA clearance. This new capital will accelerate broader platform deployment. Hospitals across the nation will gain access.
Focused efforts will support two flagship platforms. Brainomix 360 Stroke and Brainomix 360 e-Lung are prime targets. The company will also strengthen customer support. This covers both the U.S. and European markets. Product innovation will receive a significant boost. This ensures Brainomix remains at technology's forefront.
Brainomix 360 Stroke revolutionizes acute stroke assessment. It functions as a fully automated AI imaging platform. Its impact spans the entire patient pathway. The system supports faster treatment decisions. It enables more confident transfer decisions. Speed is paramount in stroke care. Every minute saved can improve patient outcomes. This technology aids clinicians significantly. It helps them act decisively.
The platform provides vital insights. It allows for swift patient triage. This is crucial for primary stroke centers. Endovascular thrombectomy treatment rates can increase. Delays in patient transfer also reduce. Brainomix 360 Stroke makes advanced stroke care more accessible. This benefits patients regardless of local resources.
Pulmonary fibrosis presents another major healthcare challenge. Brainomix addresses this with its 360 e-Lung platform. This technology utilizes AI-driven CT biomarkers. It helps identify the disease early. It also monitors disease progression. Prediction of future trends becomes possible. This enables earlier diagnosis. Consequently, earlier treatment options emerge. Improved patient outcomes for pulmonary fibrosis sufferers become a reality.
Brainomix originated as a spinout from the University of Oxford. This lineage highlights its deep scientific roots. The company operates globally. Its reach extends to over 20 countries. Offices are strategically located. They include the UK, Ireland, and the United States. This international presence facilitates widespread adoption.
The company's core mission is clear. It aims to enable precision medicine. AI-powered imaging tools drive this goal. These tools improve clinical decision-making. They lead directly to enhanced patient outcomes. Brainomix positions itself as a leader in healthcare innovation.
The investment from Modi Ventures is noteworthy. It marks a fresh U.S. commitment. Sahir Ali, Modi Ventures Founder, expressed confidence. The platform boasts rigorous clinical validation. Real-world evidence supports Brainomix 360 Stroke's efficacy. It significantly increases treatment rates. It reduces patient transfer delays.
Modi Ventures also recognized e-Lung's potential. It called the technology truly novel. It accelerates fibrosing lung disease diagnosis. This enables earlier, more effective treatment. Such advancements promise to improve patient outcomes.
This funding ensures Brainomix's sustained growth. It strengthens its research and development capabilities. The company can now accelerate new product features. It can enhance existing platform functionalities. The focus remains on delivering cutting-edge AI solutions. These solutions address critical medical needs.
AI's role in healthcare is rapidly expanding. It offers unprecedented opportunities. Diagnostics become more precise. Treatment pathways become more personalized. Brainomix stands at the forefront of this revolution. Its platforms embody the future of medical imaging. They empower clinicians with superior tools.
The healthcare landscape constantly evolves. Hospitals face increasing pressure. They must deliver efficient, high-quality care. Brainomix provides essential support. Its AI solutions streamline workflows. They enhance diagnostic accuracy. They ultimately improve patient lives. This recent funding solidifies its trajectory. It reinforces its commitment to transformative healthcare technology. Brainomix is poised for significant impact. Its global influence continues to grow. The future of AI in medicine looks brighter.